Literature DB >> 1756022

Acute phase reaction, infarct size and in-hospital morbidity in myocardial infarction patients treated with streptokinase or recombinant tissue type plasminogen activator.

K Pietilä1, A Harmoinen, A M Teppo.   

Abstract

We examined the acute phase reaction in myocardial infarction after thrombolytic treatment by streptokinase or tissue plasminogen activator. The magnitude of the acute phase reaction as determined by measurements of serum C-reactive protein and amyloid-A protein did not correlate with infarct size (determined by serial measurements of creatine kinase-MB) in this patient population. On the other hand, the development of acute cardiac failure was more closely associated with the magnitude of the acute phase reaction than with infarct size. The peak serum values of C-reactive protein in patients with and without acute cardiac failure were 128 mg/l (95% confidence intervals 85-170) and 60 mg/l (30-89); P less than 0.01 and concentration time integrals 578 mg/l x days (368-787) and 205 mg/l x days (62-350); P less than 0.01. The corresponding creatine kinase-MB values were 310 U/l (191-429) and 207 U/l (125-289) not significant; and 319 U/l x days (201-437) and 204 U/l x days (124-286) not significant; respectively. Patients requiring medication for cardiac failure on discharge from hospital had higher C-reactive protein and serum amyloid A protein values than those who did not, although the difference did not quite reach statistical significance. The infarct sizes were similar whether the patients needed medication for cardiac failure at discharge or not. Subjectively felt morbidity due to myocardial infarction was linearly associated with serum C-reactive protein peak values (P less than 0.05) and concentration time integrals (P less than 0.05), but not with infarct size. We conclude that thrombolytic treatment of myocardial infarction may reduce hospital inpatient morbidity independently of the limitation of infarct size. This diminished morbidity seems to be associated with modest or low acute phase reaction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1756022     DOI: 10.3109/07853899109150513

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  6 in total

1.  Systemic Inflammatory Response Syndrome is an Independent Predictor of One-Year Mortality in Patients with Acute Myocardial Infarction.

Authors:  Wei-Chieh Huang; Ruey-Hsing Chou; Chun-Chin Chang; Chien-Yi Hsu; Yu-Chen Ku; Hsiu-Fen Huang; Yi-Chieh Chen; Po-Hsun Huang
Journal:  Acta Cardiol Sin       Date:  2017-09       Impact factor: 2.672

2.  C-reactive protein activates complement in infarcted human myocardium.

Authors:  Remco Nijmeijer; Wim K Lagrand; Yvonne T P Lubbers; Cees A Visser; Chris J L M Meijer; Hans W M Niessen; C Erik Hack
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

3.  Serum lipids four weeks after acute myocardial infarction are a valid basis for lipid lowering intervention in patients receiving thrombolysis.

Authors:  R Carlsson; G Lindberg; L Westin; B Israelsson
Journal:  Br Heart J       Date:  1995-07

4.  Myocardial 123I-mIBG scintigraphy in relation to markers of inflammation and long-term clinical outcome in patients with stable chronic heart failure.

Authors:  Derk O Verschure; René Lutter; Berthe L F van Eck-Smit; G Aernout Somsen; Hein J Verberne
Journal:  J Nucl Cardiol       Date:  2016-11-17       Impact factor: 5.952

5.  "First in Man": Case Report of Selective C-Reactive Protein Apheresis in a Patient with Acute ST Segment Elevation Myocardial Infarction.

Authors:  Wolfgang Ries; Ahmed Sheriff; Franz Heigl; Oliver Zimmermann; Christoph D Garlichs; Jan Torzewski
Journal:  Case Rep Cardiol       Date:  2018-11-06

6.  Prognostic Impact of 9-Month High-Sensitivity C-Reactive Protein Levels on Long-Term Clinical Outcomes and In-Stent Restenosis in Patients at 9 Months after Drug-Eluting Stent Implantation.

Authors:  I-Chang Hsieh; Chun-Chi Chen; Ming-Jer Hsieh; Chia-Hung Yang; Dong-Yi Chen; Shang-Hung Chang; Chao-Yung Wang; Cheng-Hung Lee; Ming-Lung Tsai
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.